Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 8, 2017
Previous Article Next Article

Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease

Author affiliations

Abstract

The kidney is one of the body's main filtration organs, and hence, opportunity exists for designing nanomedicine that can naturally accumulate in the kidneys for renal diseases. In addition to traditional physiochemical properties for kidney accumulation, such as size and charge, synthesized nanoparticles can be conjugated with targeting ligands which further home the nanocarriers to cell types of interest. In this review, we highlight key studies that have shown success in utilizing peptide- or antibody-based ligands in nanoparticles to target the glomerulus, podocytes, or renal tubule cells in the kidney. In addition, other ligand candidates which have shown renal affinity, but have not yet been integrated into a nanoparticle are also presented. These studies can provide insight into the design of novel clinical solutions for improved detection, prevention, and treatment of renal diseases using nanomedicine efforts.

Graphical abstract: Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease

Back to tab navigation

Article information


Submitted
28 Mar 2017
Accepted
02 May 2017
First published
04 May 2017

Biomater. Sci., 2017,5, 1450-1459
Article type
Minireview

Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease

J. Wang, J. J. Masehi-Lano and E. J. Chung, Biomater. Sci., 2017, 5, 1450
DOI: 10.1039/C7BM00271H

Social activity

Search articles by author

Spotlight

Advertisements